X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist, which is being evaluated for the treatment of narcolepsy type 2 & idiopathic hypersomnia.
Lead Product(s): ALKS 2680
Therapeutic Area: Sleep Product Name: ALKS 2680
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
Nemvaleukin is an innovative engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2. It is under phase 3 clinical development for the treatment of patients with platinum-resistant epithelial ovarian cancer.
Lead Product(s): Nemvaleukin Alfa,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALKS 4230
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Mural Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
Lybalvi (olanzapine and samidorphan) is a once-daily, oral atypical antipsychotic drug. It is approved by USFDA for treatment of adults with schizophrenia, and for the treatment of adults with bipolar I disorder.
Lead Product(s): Olanzapine,Samidorphan L-Malate
Therapeutic Area: Psychiatry/Psychology Product Name: Lybalvi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
ALKS 4230 (nemvaleukin alpha) is an investigational, novel, fusion protein comprised of modified IL-2 and the high affinity IL-2 alpha receptor chain, designed to preferentially expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells.
Lead Product(s): Nemvaleukin Alfa
Therapeutic Area: Oncology Product Name: ALKS 4230
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
The results of ARTISTRY-1 for nemvaleukin alfa (ALKS 4230), demonstrated that selectively targeting IL-2 pathway may deliver significant clinical benefit in multiple tumor types while mitigating hallmark toxicities associated with high-dose recombinant-IL-2.
Lead Product(s): Nemvaleukin Alfa,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALKS 4230
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
ALKS 4230 (nemvaleukin), an investigational, novel, engineered fusion protein comprised of modified interleukin-2 and high-affinity IL-2 alpha receptor chain, designed to preferentially expand tumor-killing immune cells.
Lead Product(s): Nemvaleukin Alfa,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALKS 4230
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
LYBALVI (olanzapine and samidorphan), an atypical antipsychotic drug approved in U.S. for treatment of adults with schizophrenia and for treatment of adults with bipolar I disorder.
Lead Product(s): Olanzapine,Samidorphan L-Malate
Therapeutic Area: Psychiatry/Psychology Product Name: Lybalvi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
Nemvaleukin, an engineered fusion protein comprised of modified interleukin-2 and IL-2 alpha receptor chain, designed to preferentially expand tumor-killing immune cells while avoiding activation of immunosuppressive cells by selectively binding to IL-2 receptor complex.
Lead Product(s): Nemvaleukin Alfa,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALKS 4230
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
The study is evaluating intravenously administered nemvaleukin in patients with mucosal melanoma and subcutaneously administered nemvaleukin in patients with advanced cutaneous melanoma.
Lead Product(s): Nemvaleukin Alfa
Therapeutic Area: Oncology Product Name: ALKS 4230
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2021
Details:
The study assessed treatment patterns and HRU among 3,665 patients diagnosed with alcohol dependence who were treated with VIVITROL® (naltrexone for extended-release injectable suspension (XR-NTX)).
Lead Product(s): Naltrexone,Bupropion Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Vivitrol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
